Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep:37:27-32.
doi: 10.1016/j.npbr.2020.05.008. Epub 2020 May 31.

Neurological manifestations of COVID-19 and other coronaviruses: A systematic review

Alyne Oliveira Correia  1 , Pedro Walisson Gomes Feitosa  2 , Jorge Lucas de Sousa Moreira  2 , Samuel Átila Rodrigues Nogueira  2 , Ricardo Brandão Fonseca  1 , Maria Elizabeth Pereira Nobre  2
Affiliations
Review

Neurological manifestations of COVID-19 and other coronaviruses: A systematic review

Alyne Oliveira Correia et al. Neurol Psychiatry Brain Res. 2020 Sep.

Abstract

Objective: To describe the main neurological manifestations related to coronavirus infection in humans.

Methodology: A systematic review was conducted regarding clinical studies on cases that had neurological manifestations associated with COVID-19 and other coronaviruses. The search was carried out in the electronic databases PubMed, Scopus, Embase, and LILACS with the following keywords: "coronavirus" or "Sars-CoV-2" or "COVID-19" and "neurologic manifestations" or "neurological symptoms" or "meningitis" or "encephalitis" or "encephalopathy," following the Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

Results: Seven studies were included. Neurological alterations after CoV infection may vary from 17.3% to 36.4% and, in the pediatric age range, encephalitis may be as frequent as respiratory disorders, affecting 11 % and 12 % of patients, respectively. The Investigation included 409 patients diagnosed with CoV infection who presented neurological symptoms, with median age range varying from 3 to 62 years. The main neurological alterations were headache (69; 16.8 %), dizziness (57, 13.9 %), altered consciousness (46; 11.2 %), vomiting (26; 6.3 %), epileptic crises (7; 1.7 %), neuralgia (5; 1.2 %), and ataxia (3; 0.7 %). The main presumed diagnoses were acute viral meningitis/encephalitis in 25 (6.1 %) patients, hypoxic encephalopathy in 23 (5.6 %) patients, acute cerebrovascular disease in 6 (1.4 %) patients, 1 (0.2 %) patient with possible acute disseminated encephalomyelitis, 1 (0.2 %) patient with acute necrotizing hemorrhagic encephalopathy, and 2 (1.4 %) patients with CoV related to Guillain-Barré syndrome.

Conclusion: Coronaviruses have important neurotropic potential and they cause neurological alterations that range from mild to severe. The main neurological manifestations found were headache, dizziness and altered consciousness.

Keywords: ACE2, angiotensin converting enzyme 2; ADEM, acute disseminated encephalomyelitis; ANHE, acute necrotizing hemorrhagic encephalopathy; BBE, Bickerstaff’s encephalitis; COVID-19; COVID-19, coronavirus disease 2019; CoV, coronavirus; Coronavirus; DPP4, dipeptidil peptidase 4; Encephalopathy; G-CSF, granulocyte colony stimulating factor (G-CSF); GBS, Guillain-Barré syndrome; GM-CSF, granulocyte-macrophage colony-stimulating factor; HCoV, Human coronavirus; HCoV-229E, Human coronavirus 229E; HCoV-OC43, Human coronavirus OC43; ICU, intensive care unit; IL, interleukin; MCP-1, monocyte chemoattractant protein-1; MERS, Middle East respiratory syndrome; MERS-CoV, Middle East respiratory syndrome coronavirus; Neurologic manifestations; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; SARS, severe acute respiratory syndrome; SARS-CoV-2; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SARS‐CoV, severe acute respiratory syndrome coronavirus; βCoV, betacoronavírus.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Flowchart summarizing the search strategy for studies. Adapted from Moher et al. (2009).
See this image and copyright information in PMC

References

    1. Arabi Y.M., Harthi A., Hussein J., Bouchama A., Johani S., Hajeer A.H.…Balkhy H. Severe neurologic syndrome associated with Middle East respiratory syndrome corona virus (MERS-CoV) Infection. 2015;43(4):495–501. doi: 10.1007/s15010-015-0720-y. - DOI - PMC - PubMed
    1. Bell M.D., Taub D.D., Perry V.H. Overriding the brain’s intrinsic resistance to leukocyte recruitment with intraparenchymal injections of recombinant chemokines. Neuroscience. 1996;74(1):283–292. doi: 10.1016/0306-4522(96)00083-8. - DOI - PubMed
    1. Chen T., Wu D., Chen H., Yan W., Yang D., Chen G., Ma K., Xu D., Yu H., Wang H., Wang T., Guo W., Chen J., Ding C., Zhang X., Huang J., Han M., Li S., Luo X.…Ning Q. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study. Bmj. 2020;1091(December 2019):m1091. doi: 10.1136/bmj.m1091. - DOI - PMC - PubMed
    1. Cui J., Li F., Shi Z.L. Origin and evolution of pathogenic coronaviruses. Nature Reviews Microbiology. 2019;17(3):181–192. doi: 10.1038/s41579-018-0118-9. - DOI - PMC - PubMed
    1. Dodd D.A., Giddings T.H., Kirkegaard K. Poliovirus 3A protein limits Interleukin-6 (IL-6), IL-8, and Beta interferon secretion during viral infection. Journal of Virology. 2001;75(17):8158–8165. doi: 10.1128/jvi.75.17.8158-8165.2001. - DOI - PMC - PubMed